217 related articles for article (PubMed ID: 38253605)
1. Biophysical chemistry behind sickle cell anemia and the mechanism of voxelotor action.
Suhail M
Sci Rep; 2024 Jan; 14(1):1861. PubMed ID: 38253605
[TBL] [Abstract][Full Text] [Related]
2. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
Vichinsky E; Hoppe CC; Ataga KI; Ware RE; Nduba V; El-Beshlawy A; Hassab H; Achebe MM; Alkindi S; Brown RC; Diuguid DL; Telfer P; Tsitsikas DA; Elghandour A; Gordeuk VR; Kanter J; Abboud MR; Lehrer-Graiwer J; Tonda M; Intondi A; Tong B; Howard J;
N Engl J Med; 2019 Aug; 381(6):509-519. PubMed ID: 31199090
[TBL] [Abstract][Full Text] [Related]
3. Blocking HbS Polymerization in SCD.
Lettre G
Cell; 2020 Mar; 180(5):819. PubMed ID: 32142671
[TBL] [Abstract][Full Text] [Related]
4. Model-informed drug development of voxelotor in sickle cell disease: Exposure-response analysis to support dosing and confirm mechanism of action.
Green ML; Savic RM; Tonda M; Jorga K; Washington CB
CPT Pharmacometrics Syst Pharmacol; 2022 Jun; 11(6):698-710. PubMed ID: 35447017
[TBL] [Abstract][Full Text] [Related]
5. Voxelotor Treatment Interferes With Quantitative and Qualitative Hemoglobin Variant Analysis in Multiple Sickle Cell Disease Genotypes.
Rutherford-Parker NJ; Campbell ST; Colby JM; Shajani-Yi Z
Am J Clin Pathol; 2020 Oct; 154(5):627-634. PubMed ID: 32561909
[TBL] [Abstract][Full Text] [Related]
6. Interactions of an Anti-Sickling Drug with Hemoglobin in Red Blood Cells from a Patient with Sickle Cell Anemia.
Strader MB; Liang H; Meng F; Harper J; Ostrowski DA; Henry ER; Shet AS; Eaton WA; Thein SL; Alayash AI
Bioconjug Chem; 2019 Mar; 30(3):568-571. PubMed ID: 30794381
[TBL] [Abstract][Full Text] [Related]
7. Voxelotor for the treatment of sickle cell disease in pediatric patients.
Brown C; Tonda M; Abboud MR
Expert Rev Hematol; 2022 Jun; 15(6):485-492. PubMed ID: 35671094
[TBL] [Abstract][Full Text] [Related]
8. Systematic Review of Voxelotor: A First-in-Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease.
Han J; Saraf SL; Gordeuk VR
Pharmacotherapy; 2020 Jun; 40(6):525-534. PubMed ID: 32343424
[TBL] [Abstract][Full Text] [Related]
9. A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease.
Howard J; Hemmaway CJ; Telfer P; Layton DM; Porter J; Awogbade M; Mant T; Gretler DD; Dufu K; Hutchaleelaha A; Patel M; Siu V; Dixon S; Landsman N; Tonda M; Lehrer-Graiwer J
Blood; 2019 Apr; 133(17):1865-1875. PubMed ID: 30655275
[TBL] [Abstract][Full Text] [Related]
10. Voxelotor for the treatment of sickle cell disease.
Vissa M; Vichinsky E
Expert Rev Hematol; 2021 Mar; 14(3):253-262. PubMed ID: 33602029
[No Abstract] [Full Text] [Related]
11. Nitric oxide reduces sickle hemoglobin polymerization: potential role of nitric oxide-induced charge alteration in depolymerization.
Ikuta T; Thatte HS; Tang JX; Mukerji I; Knee K; Bridges KR; Wang S; Montero-Huerta P; Joshi RM; Head CA
Arch Biochem Biophys; 2011 Jun; 510(1):53-61. PubMed ID: 21457702
[TBL] [Abstract][Full Text] [Related]
12. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin.
Henry ER; Metaferia B; Li Q; Harper J; Best RB; Glass KE; Cellmer T; Dunkelberger EB; Conrey A; Thein SL; Bunn HF; Eaton WA
Blood; 2021 Sep; 138(13):1172-1181. PubMed ID: 34197597
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 years.
Estepp JH; Kalpatthi R; Woods G; Trompeter S; Liem RI; Sims K; Inati A; Inusa BPD; Campbell A; Piccone C; Abboud MR; Smith-Whitley K; Dixon S; Tonda M; Washington C; Griffin NM; Brown C
Pediatr Blood Cancer; 2022 Aug; 69(8):e29716. PubMed ID: 35451176
[TBL] [Abstract][Full Text] [Related]
14. Urgent use of voxelotor in sickle cell disease when immediate transfusion is not safe.
Ferlis M; Lipato T; Roseff SD; Smith WR
Eur J Haematol; 2022 Nov; 109(5):586-589. PubMed ID: 35848827
[TBL] [Abstract][Full Text] [Related]
15. Rapid and reproducible characterization of sickling during automated deoxygenation in sickle cell disease patients.
Rab MAE; van Oirschot BA; Bos J; Merkx TH; van Wesel ACW; Abdulmalik O; Safo MK; Versluijs BA; Houwing ME; Cnossen MH; Riedl J; Schutgens REG; Pasterkamp G; Bartels M; van Beers EJ; van Wijk R
Am J Hematol; 2019 May; 94(5):575-584. PubMed ID: 30784099
[TBL] [Abstract][Full Text] [Related]
16. The effect of Voxelotor on quantitation of HbS levels by high-performance liquid chromatography in a patient with sickle cell disease.
Giacomini L; Puricelli C; Sacchetti S; Zanotti V; Rolla R
Int J Lab Hematol; 2023 Dec; 45(6):831-832. PubMed ID: 37604778
[No Abstract] [Full Text] [Related]
17. PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease.
Gopalsamy A; Aulabaugh AE; Barakat A; Beaumont KC; Cabral S; Canterbury DP; Casimiro-Garcia A; Chang JS; Chen MZ; Choi C; Dow RL; Fadeyi OO; Feng X; France SP; Howard RM; Janz JM; Jasti J; Jasuja R; Jones LH; King-Ahmad A; Knee KM; Kohrt JT; Limberakis C; Liras S; Martinez CA; McClure KF; Narayanan A; Narula J; Novak JJ; O'Connell TN; Parikh MD; Piotrowski DW; Plotnikova O; Robinson RP; Sahasrabudhe PV; Sharma R; Thuma BA; Vasa D; Wei L; Wenzel AZ; Withka JM; Xiao J; Yayla HG
J Med Chem; 2021 Jan; 64(1):326-342. PubMed ID: 33356244
[TBL] [Abstract][Full Text] [Related]
18. Overview of pathophysiology and rationale for treatment of sickle cell anemia.
Rodgers GP
Semin Hematol; 1997 Jul; 34(3 Suppl 3):2-7. PubMed ID: 9317195
[TBL] [Abstract][Full Text] [Related]
19. A "Split" Hemoglobin S Peak.
Colby JM; Shajani-Yi Z
Clin Chem; 2020 Sep; 66(9):1250-1251. PubMed ID: 32870996
[No Abstract] [Full Text] [Related]
20. Vanillin, a potential agent for the treatment of sickle cell anemia.
Abraham DJ; Mehanna AS; Wireko FC; Whitney J; Thomas RP; Orringer EP
Blood; 1991 Mar; 77(6):1334-41. PubMed ID: 2001455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
